These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18340661)

  • 1. Cetuximab for colorectal cancer.
    van der Spek E; Sonke GS
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340661
    [No Abstract]   [Full Text] [Related]  

  • 2. Cetuximab for colorectal cancer.
    Roila F; Garassino MC; Mantica C
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340662
    [No Abstract]   [Full Text] [Related]  

  • 3. Cetuximab for colorectal cancer.
    Yang F; Fu D; Ni Q
    N Engl J Med; 2008 Mar; 358(11):1195; author reply 1196-7. PubMed ID: 18337611
    [No Abstract]   [Full Text] [Related]  

  • 4. Cetuximab for colorectal cancer.
    Fraggetta F; Pelosi G
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340663
    [No Abstract]   [Full Text] [Related]  

  • 5. More on cetuximab in head and neck cancer.
    Mell LK; Weichselbaum RR
    N Engl J Med; 2007 Nov; 357(21):2201-2; author reply 2202-3. PubMed ID: 18032774
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EGFR in colorectal cancer.
    Messersmith WA; Ahnen DJ
    N Engl J Med; 2008 Oct; 359(17):1834-6. PubMed ID: 18946069
    [No Abstract]   [Full Text] [Related]  

  • 8. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
    Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
    J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
    Kim R; Kubal T
    Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
    Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
    Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR antibodies in colorectal cancer: where do they belong?
    Grothey A
    J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
    [No Abstract]   [Full Text] [Related]  

  • 16. MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
    Cappuzzo F; Sacconi A; Landi L; Ludovini V; Biagioni F; D'Incecco A; Capodanno A; Salvini J; Corgna E; Cupini S; Barbara C; Fontanini G; Crinò L; Blandino G
    Clin Colorectal Cancer; 2014 Mar; 13(1):37-45.e4. PubMed ID: 24503111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panitumumab (Vectibix) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2007 Apr; 49(1259):35-6. PubMed ID: 17450113
    [No Abstract]   [Full Text] [Related]  

  • 18. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer.
    Chu E
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S60-1. PubMed ID: 16336750
    [No Abstract]   [Full Text] [Related]  

  • 20. Cetuximab.
    Graham J; Muhsin M; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Jul; 3(7):549-50. PubMed ID: 15272498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.